An ‘electric’ implant that helps broken bones mend quicker before dissolving away has been developed by scientists.
Placed over a fracture, the device, which resembles a sticking plaster, generates a mild electric current to accelerate the rate of healing.
In animal tests, a broken tibia (shin bone) knitted back together completely in just six weeks when the 1 cm-long implant was used, but took at least ten weeks when it was not.
After 18 weeks, there was no sign of the implant, which is made from a biodegradable man-made material, called poly lactic-co-glycolic acid, or PLGA, the journal Proceedings of the National Academy of Sciences reported earlier this month.
In Vitro Diagnostics (IVD) Quality Control Market Size, Growth, Share, Trends, Competitive Landscape, Regional Analysis 2031 | Thermo Fisher Scientific, Inc , Bio-Rad Laboratories, Inc , Sero AS, Siemens Healthcare GmbH, – KSU
ksusentinel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ksusentinel.com Daily Mail and Mail on Sunday newspapers.
HORIBA Medical and CEA-Leti strengthen their partnership to develop tomorrows diagnostics at the point of care
pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.
NIMIUM Therapeutics und Paraza Pharma schließen Partnerschaft zur Entwicklung neuer Medikamente zur Behandlung von kardiometabolischen Erkrankungen (CMDs), Fettleibigkeit und Typ-2-Diabetes
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Apollon Formularies Plc (AQSE: APOL) ( Apollon or the Company ), a UK based international pharmaceutical company trading on the Aquis Stock Exchange is pleased to announce that its medical cannabis formulations were shown to be effective in killing both hormone-resistant and hormone-sensitive prostate cancer cells in 3D cell cultures in third party independent laboratory testing. ¹ This finding is in addition to the results recently announced on May 18, 2021² that Apollon formulations were successful in killing HER2+ breast cancer cells, and the announcement on June 28, 2021³ that Apollon formulations were successful in killing triple-negative breast cancer cells. This testing was performed under a joint testing agreement with Aion Therapeutic Inc. (CSE: AION) ( Aion ),a BC based international pharmaceutical company trading on the Canadian Securities Exchange.